“内外”兼修 西藏药业转型谋新篇

Core Viewpoint - Tibet Pharmaceutical is focusing on both internal growth and external expansion to reduce its reliance on a single product, New Huoshu, and to explore new growth opportunities in innovative drug development [7][12]. Internal Growth - Tibet Pharmaceutical has established a comprehensive industry layout over the past two decades, covering markets in Tibet, Sichuan, Shanghai, and overseas [8]. - The company’s product range includes biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, with key products addressing cardiovascular, liver, and respiratory conditions [8]. - New Huoshu, a self-developed biopharmaceutical for acute heart failure, has maintained stable sales revenue, and the company plans to invest several million yuan in evidence-based medical research to expand its application scenarios [8][9]. - The company has established a Tibetan medicinal material planting research base to ensure a stable supply of core medicinal materials, while also promoting ecological protection [9]. External Expansion - Tibet Pharmaceutical is investing in innovative drug fields, particularly gene editing, through its wholly-owned subsidiary TopRidge Pharma Limited, with a $60 million investment in Accuredit Therapeutics Limited [10][11]. - Accuredit Therapeutics focuses on developing in vivo gene editing technologies and aims to provide cost-effective innovative treatment solutions [11]. - The company has also invested 300 million yuan in Jiangsu Chentai Pharmaceutical Technology Co., acquiring a 13.04% stake, with Chentai's drug Zorifertinib showing significant results in clinical trials for advanced non-small cell lung cancer [12]. - The company aims to enhance its R&D capabilities and product pipeline through strategic investments and partnerships, ensuring long-term sustainable growth [12][13].